European Radiology:这些影像学征象,进一步提高了临床对急性缺血性卒中预后的预测能力!

2022-09-14 shaosai MedSci原创

小血管病变(SVD)的一般影像学标志物,包括脑萎缩、脑白质疏松症、裂隙和血管周围间隙扩大(EPVS),在AIS中普遍存在。

现阶段侧支循环状态被认为是预测大血管闭塞性卒中组织情况和临床预后的主要因素之一。在急性缺血性卒中(AIS)期间,强大的侧支循环可以通过重新分配缺血区的血流保护缺血半暗带发生进一步的梗死来达到减缓病情发展、改善再灌注。

小血管病变(SVD)的一般影像学标志物,包括脑萎缩、脑白质疏松症、裂隙和血管周围间隙扩大(EPVS),在AIS中普遍存在。以前的研究认为,SVD是较差侧支循环存在的决定因素。此外,SVD的存在还可能使AIS的预后恶化。据我们所知很少有研究在评估卒中预后时同时考虑SVD的情况这可能低估了评估AIS和预测其预后的作用。

近日,发表在European Radiology杂志的一项研究评估了SVD指标与不利的临床预后之间的关系,并进一步验证SVD指标在决定近端血管闭塞/严重狭窄AIS患者临床预后中的额外价值。

本研究回顾了2018年10月1日至2021年10月31日期间,在症状发生后24小时内进行基线CTA并在入院后5天进行MRI扫描的大血管卒中患者。在CT血管造影和MR图像上分别对颈动脉和SVD指标(包括萎缩、脑白质疏松症、裂隙和血管周围间隙)进行了分级。记录了90天时的修正兰金量表(mRS)评分,mRS≤2被认为是一个良好的临床结果。使用逻辑和因果调解回归法分析了SVD标志物和mRS之间的关联。 

本研究最终招募了119名患者(70±13岁)。多变量回归显示萎缩(证据。OR 0.05 [95% CI 0.01-0.31], p = 0.002; 严重。OR 0.08 [95% CI 0.01-0.44], p = 0.007)和裂隙(OR 0.30 [95% CI 0.08-0.96], p = 0.049)与校正协变量后的不良临床结果有关。采用具有萎缩和裂隙的分类模型在区分较好及较差临床结果AUC明显高于没有使用指标的模型(p = 0.036)。 


 预测急性缺血性卒中后良好临床预后(mRS≤2 vs mRS>2)的AUC下面积。有SVD标志物的模型中的变量包括脑萎缩、裂隙、侧枝状态、年龄、性别、NIHSS、TICI 2b/3和最终梗塞体积。DeLong检验显示这两个模型之间存在明显差异

本研究表明,脑萎缩和裂隙两者作为评估中重要的影像学标志物,可以额外提高对AIS后临床结果的预测。

原文出处:

Jia-Ying Zhou,Yi-Bin Shi,Cong Xia,et al.Beyond collaterals: brain frailty additionally improves prediction of clinical outcome in acute ischemic stroke.DOI:10.1007/s00330-022-08792-6

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1893556, encodeId=ad1c189355629, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Mon Mar 27 12:00:09 CST 2023, time=2023-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806548, encodeId=fa471806548d6, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Sat Aug 26 01:00:09 CST 2023, time=2023-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729813, encodeId=eb8b1e2981398, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Mon Apr 17 12:00:09 CST 2023, time=2023-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248952, encodeId=920e124895293, content=感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=82f85718682, createdName=ms6000001171760310, createdTime=Wed Sep 14 21:29:54 CST 2022, time=2022-09-14, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1893556, encodeId=ad1c189355629, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Mon Mar 27 12:00:09 CST 2023, time=2023-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806548, encodeId=fa471806548d6, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Sat Aug 26 01:00:09 CST 2023, time=2023-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729813, encodeId=eb8b1e2981398, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Mon Apr 17 12:00:09 CST 2023, time=2023-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248952, encodeId=920e124895293, content=感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=82f85718682, createdName=ms6000001171760310, createdTime=Wed Sep 14 21:29:54 CST 2022, time=2022-09-14, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1893556, encodeId=ad1c189355629, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Mon Mar 27 12:00:09 CST 2023, time=2023-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806548, encodeId=fa471806548d6, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Sat Aug 26 01:00:09 CST 2023, time=2023-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729813, encodeId=eb8b1e2981398, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Mon Apr 17 12:00:09 CST 2023, time=2023-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248952, encodeId=920e124895293, content=感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=82f85718682, createdName=ms6000001171760310, createdTime=Wed Sep 14 21:29:54 CST 2022, time=2022-09-14, status=1, ipAttribution=)]
    2023-04-17 feather89
  4. [GetPortalCommentsPageByObjectIdResponse(id=1893556, encodeId=ad1c189355629, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Mon Mar 27 12:00:09 CST 2023, time=2023-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806548, encodeId=fa471806548d6, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Sat Aug 26 01:00:09 CST 2023, time=2023-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729813, encodeId=eb8b1e2981398, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Mon Apr 17 12:00:09 CST 2023, time=2023-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248952, encodeId=920e124895293, content=感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=82f85718682, createdName=ms6000001171760310, createdTime=Wed Sep 14 21:29:54 CST 2022, time=2022-09-14, status=1, ipAttribution=)]
    2022-09-14 ms6000001171760310

    感谢分享

    0

相关资讯

NEUROLOGY:无效再通治疗的多变量预测模型有助于急性缺血性卒中患者临床决策

预测算法将有助于为共享决策提供信息,并设定现实的期望。尽管该算法在医疗资源高的情况下拒绝治疗的临床效益和可用性有待于未来的研究,但开发一种预测FRT的可靠算法似乎是可以实现的,并应纳入更先进的入院影像

Neurology:急性缺血性卒中患者凝血酶生成与白细胞炎症状态的关系

血栓形成是急性缺血性卒中发病机制的核心,凝血酶生成增加与卒中风险增加有关。已识别的基因和途径支持免疫系统在中风患者血栓形成中的作用。这些可能与卒中预防的抗血栓策略有关。

Lancet:替奈普酶 vs 阿替普酶治疗急性缺血性卒中的效果

对于所有符合溶栓标准的急性缺血性卒中患者,静脉注射替奈普酶(0.25mg/kg)是阿替普酶的合理替代方案、

JNNP:急性缺血性卒中成功取栓治疗后与早期神经功能改善相关

早期神经功能改善(ENI)定义为急性缺血性卒中(AIS)治疗24小时后,美国国立卫生研究院卒中量表(NIHSS)评分为0或1或改善8分,是AIS患者良好长期临床结果的有力预测因子。静脉溶栓或血管内取栓

Neurology:血浆可溶性二肽基肽酶4与缺血性卒中后主要心血管事件的风险:中国急性缺血性卒中抗高血压试验(CATIS)的二次分析

研究发现急性缺血性卒中患者血浆sDPP4水平较高与缺血性卒中后心血管事件、复发性卒中、全因死亡率和功能不良结局的风险降低相关,这表明血浆sDPP4可能是急性缺血性卒中患者初始危险分层的潜在预后标志物。

Euro Radio颈动脉易损斑块与脑小血管疾病及急性缺血性卒中的相关性

斑块内出血(IPH)、薄或破裂的纤维帽(FC)和不规则的斑块表面等易损斑块特征是评估缺血性卒中风险的有效指标。